July 24, 2023
Daiichi Sankyo’s FLT3 inhibitor Vanflyta (quizartinib) gained US approval on July 20, four years after its initial Japanese blessing and rejection by the FDA. The drug is now approved for the first-line treatment of acute myeloid leukemia (AML) with FLT3-ITD...read more